UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 238

Sortiert nach

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

Lancet neurology, 2014-03, Vol.13 (3), p.257-267

2014

Link zum Volltext

Verfügbarkeit prüfen

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

Drugs (New York, N.Y.), 2020-12, Vol.80 (18), p.1901-1928

2020

Link zum Volltext

Verfügbarkeit prüfen

Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy

The Journal of immunology (1950), 2015-06, Vol.194 (11), p.5085-5093

2015

Link zum Volltext

Verfügbarkeit prüfen

Cladribine: mode of action and implications for treatment of multiple sclerosis

Clinical neuropharmacology, 2011-01, Vol.34 (1), p.28-35

2011

Link zum Volltext

Verfügbarkeit prüfen

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

Multiple Sclerosis Journal, 2023-05, Vol.29 (6), p.648-656

2023

Link zum Volltext

Verfügbarkeit prüfen

Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability

Health psychology & behavioral medicine, 2022-12, Vol.10 (1), p.316-334

2022

Link zum Volltext

Verfügbarkeit prüfen

Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis

Value in health, 2019-04, Vol.22 (4), p.453-466

2019

Link zum Volltext

Verfügbarkeit prüfen

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Multiple sclerosis, 2022-04, Vol.28 (5), p.790-800

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Therapeutic advances in neurological disorders, 2019-06, Vol.12, p.1756286419854986-1756286419854986

2019

Link zum Volltext

Verfügbarkeit prüfen

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment

Scientific reports, 2023-05, Vol.13 (1), p.8067-8067, Article 8067

2023

Link zum Volltext

Verfügbarkeit prüfen

Challenges in multiple sclerosis care: Results from an international mixed-methods study

Multiple sclerosis and related disorders, 2021-05, Vol.50, p.102854-102854, Article 102854

2021

Link zum Volltext

Verfügbarkeit prüfen

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

Frontiers in immunology, 2021-12, Vol.12, p.763433-763433

2021

Link zum Volltext

Verfügbarkeit prüfen

A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy

Multiple sclerosis and related disorders, 2023-10, Vol.78, p.104917-104917, Article 104917

2023

Link zum Volltext

Verfügbarkeit prüfen

Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary

Future oncology (London, England), 2022-02, Vol.12 (1), p.1-7

2022

Link zum Volltext

Verfügbarkeit prüfen

N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study

Frontiers in neurology, 2020-02, Vol.11, p.88

2020

Link zum Volltext

Verfügbarkeit prüfen

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

Current medical research and opinion, 2007-11, Vol.23 (11), p.2667-2676

2007

Link zum Volltext

Verfügbarkeit prüfen

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

Neurology : neuroimmunology & neuroinflammation, 2018-09, Vol.5 (5), p.e477-e477

2018

Link zum Volltext

Verfügbarkeit prüfen

Involvement of beta-chemokines in the development of inflammatory demyelination

Journal of neuroinflammation, 2005-02, Vol.2 (1), p.7-7, Article 7

2005

Link zum Volltext

Verfügbarkeit prüfen

Physician Compensation in the United States – Through the Lens of the MS Neurologist

Multiple sclerosis and related disorders, 2021-05, Vol.50, p.102847-102847, Article 102847

2021

Link zum Volltext

Verfügbarkeit prüfen

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Multiple sclerosis and related disorders, 2016-01, Vol.5, p.97-104

2016

Link zum Volltext

Verfügbarkeit prüfen

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary

Neurodegenerative disease management, 2022-12, Vol.12 (6), p.303-310

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: assessing absolute differences using a number needed to treat analysis

Multiple sclerosis and related disorders, 2016-11, Vol.10, p.204-212

2016

Link zum Volltext

Verfügbarkeit prüfen

N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis

Heliyon, 2021-07, Vol.7 (7), p.e07615-e07615, Article e07615

2021

Link zum Volltext

Verfügbarkeit prüfen

Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics

Neurology, 2010-01, Vol.74 Suppl 1, p.S54

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis

Journal of neuroimaging, 2005-01, Vol.15 (s4), p.10S-21S

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(216)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy

Cladribine: mode of action and implications for treatment of multiple sclerosis

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability

Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment

Challenges in multiple sclerosis care: Results from an international mixed-methods study

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy

Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary

N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

Involvement of beta-chemokines in the development of inflammatory demyelination

Physician Compensation in the United States – Through the Lens of the MS Neurologist

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: assessing absolute differences using a number needed to treat analysis

N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis

Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics

Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis

Suchergebnisse filtern